1. TSG101: Tumor Susceptibility Gene 101 (tsg101) Product-Role in Therapy Against HIV/AIDS.
- Author
-
Qadir MI and Zafar M
- Subjects
- Acquired Immunodeficiency Syndrome immunology, Acquired Immunodeficiency Syndrome virology, Anti-HIV Agents immunology, Antibodies, Monoclonal immunology, DNA-Binding Proteins antagonists & inhibitors, DNA-Binding Proteins therapeutic use, Endosomal Sorting Complexes Required for Transport antagonists & inhibitors, Endosomal Sorting Complexes Required for Transport therapeutic use, HIV Infections drug therapy, HIV Infections immunology, HIV Infections virology, Humans, Transcription Factors antagonists & inhibitors, Transcription Factors therapeutic use, Acquired Immunodeficiency Syndrome drug therapy, Anti-HIV Agents therapeutic use, Antibodies, Monoclonal therapeutic use, DNA-Binding Proteins immunology, Endosomal Sorting Complexes Required for Transport immunology, Transcription Factors immunology
- Abstract
HIV infection presents a major community health hazard, partially because the HIV virus is capable of evading antiretroviral therapies. Most anti-HIV drugs were intended to target virus-encoded mechanisms; however, some host-encoded molecules comparatively execute a vital role in the life cycle of virus. Thus, these might be considered as target sites for antiviral agents. TSG101 is important among these antiviral therapies because, as a cytoplasmic molecule, it facilitates viral budding and release. In this review, HIV-infected cells have TSG101 on their surface and thus can be used in antibody-based therapies. The development of a monoclonal antibody CB8-2 lessens the assembly of viruses from infected cells. This mechanism represents the potential use of TSG101-directed antibodies to fight against AIDS.
- Published
- 2017
- Full Text
- View/download PDF